BlinkLab Forges Crucial Partnership to Advance Neurodevelopmental Disorder Research
BlinkLab (ASX: BB1), a company at the forefront of autism diagnostics, has announced a significant new collaboration with the US-based SHANK2 Foundation. This partnership is set to drive progress in understanding and addressing SHANK2-related neurodevelopmental disorders, a critical area within the broader autism spectrum.
The core objectives of this alliance are multifaceted, encompassing vital work in advocacy, raising public awareness, establishing robust research infrastructure, and facilitating comprehensive data collection. A key focus will be on assisting with phenotyping studies, which involve detailed observation and recording of observable traits and characteristics of individuals with these specific genetic conditions.
Understanding the SHANK2 Gene and its Impact
The SHANK2 gene plays an indispensable role in the intricate workings of the brain. It is fundamental to how brain cells establish and maintain synaptic connections – the critical junctions that enable communication between neurons. These connections are the bedrock of essential cognitive functions such as learning, memory formation, and complex behaviours.
When mutations occur within the SHANK2 gene, these vital neural signalling pathways become disrupted. This disruption is strongly implicated in the development of autism and a range of other neurodevelopmental disorders. The consequences can be far-reaching, often manifesting as developmental delays, significant difficulties with communication, and challenges with sensory processing.
Because SHANK2-related disorders stem from a precisely identified genetic cause, they offer a valuable and well-defined model for researchers. This genetic clarity allows for a more focused investigation into the underlying biological mechanisms of autism and related conditions. Studying these disorders can shed light on broader issues such as cognitive impairment, general developmental delays, and the occurrence of epilepsy.
A Strategic Expansion for BlinkLab
Dr Henk-Jan Boele, MD and CEO of BlinkLab, highlighted how this collaboration aligns perfectly with the company’s strategic vision. “The collaboration with the SHANK2 Foundation strongly supports BlinkLab’s strategy to broaden our digital neurodiagnostic platform into genetically defined neurodevelopmental disorders and rare disease research,” he stated.
Dr Boele elaborated on the advantages of focusing on genetically defined conditions. “Genetically defined conditions provide well-characterised patient populations that can strengthen digital biomarker validation and support the development of more precise digital phenotyping approaches,” he explained. This means that by working with individuals who have a confirmed genetic link to their condition, BlinkLab can more effectively test and refine its diagnostic tools.
BlinkLab is actively developing a cutting-edge, smartphone-based diagnostic platform specifically designed for autism. Their flagship product, BlinkLab Dx 1, is an innovative diagnostic aid for clinicians. This tool harnesses the power of smartphones, advanced artificial intelligence (AI), and machine learning to capture objective, reflex-based measures. The ultimate goal is to facilitate earlier and more accurate identification of autism in children and adults.
Accessing Genetically Confirmed Patient Populations
The partnership with the SHANK2 Foundation provides BlinkLab with invaluable access to genetically confirmed patient populations. Dr Boele expressed his enthusiasm, stating, “It’s a great honour to work with Ben Hutz and the SHANK2 foundation. The first children have already been successfully tested, and we are deeply grateful to the SHANK2 children and families worldwide participating in this important study.”
The challenges in autism research are well-documented, often stemming from misdiagnoses, the inherent heterogeneity of the autism spectrum, and diagnostic uncertainties. Dr Boele underscored the importance of this collaboration in navigating these complexities. “In the autism field, it is essential to work with well-defined patient groups, since establishing ground truth in autism research can be challenging due to misdiagnoses, heterogeneous populations, and diagnostic uncertainty,” he noted.
This initiative is expected to provide crucial external validation for BlinkLab’s smartphone-based neurometric assessments. Beyond human studies, the company plans to extend its research. In conjunction with the SCANNER consortium and through Dr Boele’s role as Assistant Professor at Erasmus MC, they will also investigate mouse models that carry the identical SHANK2 mutation. This will allow for rigorous evaluation of potential treatment effectiveness in a preclinical setting.
Advancing Digital Biomarkers
SHANK2-related disorders, being genetically defined, create a biologically characterised cohort. This cohort is ideally suited for evaluating BlinkLab’s digital behavioural biomarkers. These biomarkers, captured through the company’s innovative technology, offer a novel way to objectively measure and track developmental and neurological progress.
The market has responded positively to this news, with BlinkLab (BB1) shares seeing an increase of 4.14% to 88.0¢, bringing its market capitalisation to $106.3 million. This partnership marks a significant step forward for BlinkLab and offers renewed hope for individuals and families affected by SHANK2-related neurodevelopmental disorders.
